Goldman Sachs Maintains Buy on Fulcrum Therapeutics, Lowers Price Target to $9
Goldman Sachs analyst Madhu Kumar maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and lowers the price target from $17 to $9.
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to $5.51 in pre-market trading.
Credit Suisse Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $8
Credit Suisse analyst Judah Frommer downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Neutral and lowers the price target from $11 to $8.
Dow Up 150 Points; US Weekly Jobless Claims Rise
U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.46% to 32,948.78 while the NASDAQ rose 0.27% to 11,607.61. The S&P 500 also rose, gaining, 0.36% to 4,006.30.
Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Morgan Stanley Downgrades Fulcrum Therapeutics to Equal-Weight, Lowers Price Target to $8
Morgan Stanley analyst Matthew Harrison downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Overweight to Equal-Weight and lowers the price target from $27 to $8.
Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $20
Oppenheimer analyst Matthew Biegler maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price target from $26 to $20.
Credit Suisse Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $11
Credit Suisse analyst Judah Frommer maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price target from $19 to $11.
Dow Dips 350 Points; S&P 500 Down Over 1%
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday.
The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500 also fell, dropping, 1.23% to 3,963.05
FDA Slams Break On Fulcrum Therapeutics’ Sickle Cell Disease Study, Shares Plummet
The FDA verbally informed Fulcrum Therapeutics Inc (NASDAQ:FULC) that it has issued a full clinical hold regarding the Investigational New Drug (IND)…